What are the indications, contraindications, recommended dosing regimens, and monitoring guidelines for beta‑blocker therapy in adults with documented coronary artery disease?

Beta-Blocker Therapy in Coronary Artery Disease

Long-term beta-blocker therapy is not recommended to improve outcomes in patients with chronic coronary disease (CCD) in the absence of myocardial infarction in the past year, left ventricular ejection fraction ≤50%, or another primary indication for beta-blocker therapy. 1

Indications for Beta-Blocker Therapy

Class I (Strong) Indications

Post-Myocardial Infarction:

• Beta-blockers should be started and continued for 3 years minimum in all patients with normal LV function after MI or acute coronary syndrome 1
• For patients with MI, acute coronary syndrome, or LV dysfunction with or without heart failure symptoms, beta-blocker therapy should be started and continued indefinitely unless contraindicated 1

Reduced Left Ventricular Function:

• Beta-blocker therapy is mandatory in all patients with LV systolic dysfunction (ejection fraction ≤40%) with heart failure or prior MI 1
• Only three beta-blockers have proven mortality reduction: carvedilol, metoprolol succinate (sustained-release), and bisoprolol 1

Acute Coronary Syndromes:

• Oral beta-blockers should be initiated within the first 24 hours in patients with NSTE-ACS in the absence of heart failure, low-output state, risk for cardiogenic shock, or other contraindications 1
• The first dose may be administered intravenously if there is ongoing chest pain, followed by oral administration 1

Class IIa (Moderate) Indications

Post-MI Beyond 3 Years:

• It is reasonable to continue beta-blockers beyond 3 years as long-term therapy for hypertension in adults who have had MI or acute coronary syndrome 1

Stable Ischemic Heart Disease with Hypertension:

• Beta-blockers (along with ACE inhibitors or ARBs) should be considered as first-line therapy for compelling indications (previous MI, stable angina) in patients with stable ischemic heart disease and hypertension (BP ≥130/80 mm Hg) 1

Class IIb (Weak) or Not Recommended

Chronic Stable CAD Without Recent MI:

• Beta-blockers may be considered as chronic therapy for all other patients with coronary or other vascular disease, but evidence is limited 1
• Recent evidence shows beta-blockers were associated with only a small reduction in cardiovascular events (absolute risk reduction: -1.8%) in stable CAD patients without heart failure or recent MI 2
• The 2023 AHA/ACC guidelines explicitly state that long-term beta-blocker therapy is NOT recommended to improve outcomes in CCD patients without MI in the past year or LVEF ≤50% 1

Contraindications

Absolute Contraindications 3, 4

• Severe bradycardia (heart rate <50 beats/min)
• Preexisting sick sinus syndrome
• Second- or third-degree atrioventricular block without a cardiac pacemaker
• Severe left ventricular dysfunction with decompensated heart failure
• Active peripheral vascular disease with rest ischemia
• Reactive airway disease so severe that airway support is required
• Cardiogenic shock or hemodynamic instability 1

Relative Contraindications (Use with Caution) 3, 4

Peripheral Arterial Disease:

• Beta-blockers should be avoided only in patients with vasospastic disorders, rest pain with severe peripheral vascular disease, or nonhealing lesions
• In mild to moderate disease, beta-blockers can be prescribed with careful surveillance for changes in intermittent claudication symptoms

Diabetes Mellitus:

• Beta-blockers are NOT contraindicated in diabetic patients, including those on insulin 3, 4
• Patients must routinely monitor blood glucose levels due to potential masking of hypoglycemia symptoms
• Greater caution is needed with oral long-acting antidiabetic drugs due to risk of prolonged, paucisymptomatic hypoglycemia

Chronic Obstructive Pulmonary Disease:

• Beta-blockers are contraindicated when: (a) history of asthma is present, (b) COPD is moderate to severe (FEV1 <50% predicted), (c) patients are on chronic bronchodilator treatment, or (d) ≥20% reversibility in airway obstruction with inhaled salbutamol 4
• When FEV1 is >50% of predicted value, beta-blockers can be given with adequate monitoring of ventilatory stability
• Cardioselective beta-blockers (beta-1 selective) are preferred to minimize bronchospasm risk 3

Recommended Dosing Regimens

Oral Beta-Blockers for Chronic Therapy 1

Metoprolol:

• Immediate-release (tartrate): 50-200 mg twice daily
• Sustained-release (succinate): Target dose for heart failure indications

Carvedilol:

• Starting dose: 6.25 mg twice daily
• Uptitrate to maximum of 25 mg twice daily

Bisoprolol:

• 10 mg once daily

Atenolol:

• 50-200 mg once daily

Propranolol:

• 20-80 mg twice daily

Intravenous Beta-Blockers for Acute Settings 1

Metoprolol IV (when indicated):

• 5 mg increments by slow IV administration (5 mg over 1-2 minutes)
• Repeat every 5 minutes for total initial dose of 15 mg
• After tolerating full 15 mg IV dose, start oral therapy 15 minutes after last IV dose at 25-50 mg every 6 hours for 48 hours
• Maintenance dose: up to 100 mg twice daily

Esmolol (for hypertensive emergencies):

• Loading dose: 500-1000 mcg/kg/min over 1 minute
• Followed by 50 mcg/kg/min infusion
• Increase in 50 mcg/kg/min increments as needed to maximum of 200 mcg/kg/min 1

Important: Early aggressive IV beta-blockade poses substantial net hazard in hemodynamically unstable patients and should be avoided 1. Risk factors for shock include older age, female sex, time delay, higher Killip class, lower blood pressure, higher heart rate, and previous hypertension 1.

Monitoring Guidelines

Initial Monitoring During IV Administration 1

• Frequent checks of heart rate and blood pressure
• Continuous ECG monitoring
• Auscultation for rales and bronchospasm

Follow-up After Initiating Therapy 1

• Adults initiating a new or adjusted beta-blocker regimen should have follow-up evaluation of adherence and response to treatment at monthly intervals until control is achieved 1
• Target heart rate: 50-60 beats/min is ideal, though only 5.3% of patients achieve this throughout hospitalization 5
• Average achieved heart rate in contemporary practice is approximately 74 beats/min 5

Titration Strategy 1

• Beta-blocker therapy should be initiated at a low dose and only in stable patients
• Initiation is recommended after optimization of volume status and successful discontinuation of IV diuretics, vasodilators, and inotropic agents 1
• Caution should be used when initiating beta-blockers in patients who have required inotropes during their hospital course 1
• Only 52% of patients have dosage increases during hospitalization, with average discharge doses of metoprolol at 88 mg daily compared to admission doses of 58 mg daily 5

Re-evaluation 1

• Re-evaluate patients with initial contraindications to beta-blockers to determine subsequent eligibility as clinical status changes 1

Common Pitfalls and Caveats

Overuse in Stable CAD:

• The most significant recent change is that beta-blockers are no longer recommended for long-term use in stable CAD patients without recent MI (<1 year) or reduced LVEF 1
• Recent data from 2025 showed early beta-blocker initiation after PCI for stable CAD with preserved LVEF was associated with higher mortality (HR: 1.11) with no impact on cardiovascular events 6

Underuse in Appropriate Populations:

• Beta-blockers remain significantly underused in elderly patients and those with comorbid conditions despite proven mortality benefits (19-48% decrease in mortality, up to 28% decrease in reinfarction rates) 3
• The elderly should be started on low doses with slow titration due to increased risk of low cardiac output and bradycardia 3

Hemodynamic Instability:

• IV beta-blockers are potentially harmful when risk factors for shock are present 1
• The COMMIT study showed early aggressive beta-blockade increased cardiogenic shock, particularly in hemodynamically compromised patients 1

Choice of Agent:

• For patients with concomitant heart failure and reduced systolic function, use only the three proven agents: sustained-release metoprolol succinate, carvedilol, or bisoprolol 1
• Immediate-release nifedipine (a calcium channel blocker) is contraindicated in the absence of a beta-blocker 1

Antianginal Therapy:

• Either a calcium channel blocker or beta-blocker is recommended as first-line antianginal therapy—beta-blockers are no longer the sole first-line option 1
• Short-acting nitrates are recommended for immediate relief of angina 1